Maveropepimut-S, an immune-educating therapy with durable clinical benefit in patients with recurrent ovarian cancer (180)

Various studies have demonstrated a strong association between higher tumor T-cell infiltration and improved survival in ovarian cancer, providing a rationale to develop T-cell-activating immunotherapies. Maveropepimut-S (MVP-S) leverages the DPX platform, a non-aqueous, lipid-based delivery platform that stimulates specific and persistent immune responses to survivin peptides. Survivin is a cancer-associated protein commonly upregulated in several malignancies, including ovarian cancer. In the prior first-in-human study, MVP-S with intermittent low-dose cyclophosphamide (CPA) induced strong, durable, and polyfunctional antigen-specific CD8+ T-cell responses in ovarian cancer patients.